Brokerages predict that Cytosorbents Corp (NASDAQ:CTSO) will announce earnings per share (EPS) of ($0.08) for the current quarter, according to Zacks. Six analysts have issued estimates for Cytosorbents’ earnings, with the lowest EPS estimate coming in at ($0.09) and the highest estimate coming in at ($0.05). Cytosorbents posted earnings per share of ($0.21) in the same quarter last year, which would suggest a positive year over year growth rate of 61.9%. The business is scheduled to report its next quarterly earnings report on Tuesday, November 3rd.
According to Zacks, analysts expect that Cytosorbents will report full-year earnings of ($0.31) per share for the current financial year, with EPS estimates ranging from ($0.37) to ($0.23). For the next year, analysts expect that the business will report earnings of ($0.06) per share, with EPS estimates ranging from ($0.36) to $0.23. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Cytosorbents.
Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.08). The business had revenue of $9.80 million during the quarter, compared to analysts’ expectations of $9.79 million. Cytosorbents had a negative return on equity of 122.99% and a negative net margin of 53.56%.
Several research analysts recently weighed in on the company. SVB Leerink assumed coverage on Cytosorbents in a research report on Tuesday, September 1st. They issued an “outperform” rating and a $15.00 price objective for the company. ValuEngine upgraded Cytosorbents from a “hold” rating to a “buy” rating in a research report on Monday, August 3rd. B. Riley reiterated a “buy” rating on shares of Cytosorbents in a research report on Thursday, July 23rd. Finally, BidaskClub lowered Cytosorbents from a “buy” rating to a “hold” rating in a research report on Tuesday, August 25th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $15.20.
Large investors have recently added to or reduced their stakes in the business. Bank of Montreal Can lifted its stake in Cytosorbents by 528.0% during the second quarter. Bank of Montreal Can now owns 3,278 shares of the medical research company’s stock worth $33,000 after purchasing an additional 2,756 shares in the last quarter. Eudaimonia Partners LLC acquired a new position in Cytosorbents during the first quarter worth $54,000. Citigroup Inc. lifted its stake in Cytosorbents by 40.3% during the first quarter. Citigroup Inc. now owns 8,819 shares of the medical research company’s stock worth $68,000 after purchasing an additional 2,531 shares in the last quarter. Royal Bank of Canada lifted its stake in Cytosorbents by 51.9% during the first quarter. Royal Bank of Canada now owns 8,857 shares of the medical research company’s stock worth $68,000 after purchasing an additional 3,027 shares in the last quarter. Finally, BNP Paribas Arbitrage SA lifted its stake in Cytosorbents by 121.2% during the first quarter. BNP Paribas Arbitrage SA now owns 9,435 shares of the medical research company’s stock worth $73,000 after purchasing an additional 5,169 shares in the last quarter. Institutional investors own 26.11% of the company’s stock.
NASDAQ:CTSO traded down $0.25 during trading hours on Tuesday, hitting $7.46. 487,231 shares of the stock were exchanged, compared to its average volume of 399,424. Cytosorbents has a 52-week low of $3.49 and a 52-week high of $11.74. The firm’s fifty day moving average price is $9.27 and its 200 day moving average price is $8.39. The company has a current ratio of 2.68, a quick ratio of 2.55 and a debt-to-equity ratio of 0.38. The company has a market cap of $321.96 million, a P/E ratio of -14.35 and a beta of 0.48.
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
See Also: How to identify percentage decliners
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.